Jiangxi Rimag Group Co., Ltd. Class H (HK:2522)
:2522
Top Page
Jiangxi Rimag Group Co., Ltd. Class H
(2522)
Select Model
Select Model
Rating:51Neutral
Price Target:
HK$5.50
▼(-32.10% Downside)
Action:ReiteratedDate:04/02/26
The score reflects a moderate financial recovery (return to growth, positive earnings, and improved operating cash flow) offset by weak technical trends (price well below key moving averages with negative MACD) and a rich valuation (P/E 68.4 with no dividend yield provided), leaving limited margin for error given historically volatile profits and free cash flow.
Positive Factors
Operating cash flow recovery
A large improvement in operating cash flow to 177.4M in 2025 signals the company can convert sales into cash more reliably than in 2024. Sustained OCF recovery reduces refinancing risk, supports working capital and capex, and underpins durable cash generation over coming quarters.
Negative Factors
Volatile free cash flow
Large year-to-year swings in free cash flow indicate cash available to investors is unstable. Persistent FCF volatility can constrain dividends, buybacks, or debt reduction plans and forces conservative liquidity management, limiting the company's ability to execute strategic initiatives reliably.
Read all positive and negative factors
Positive Factors
Negative Factors
Operating cash flow recovery
A large improvement in operating cash flow to 177.4M in 2025 signals the company can convert sales into cash more reliably than in 2024. Sustained OCF recovery reduces refinancing risk, supports working capital and capex, and underpins durable cash generation over coming quarters.
Read all positive factors
Jiangxi Rimag Group Co., Ltd. Class H (2522) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.26B
Dividend YieldN/A
Average Volume (3M)10.53M
Price to Earnings (P/E)705.2
Beta (1Y)1.04
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees1,342
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.04
Shares Outstanding294,128,080
10 Day Avg. Volume6,254,929
30 Day Avg. Volume10,530,505
Financial Highlights & Ratios
PEG Ratio-6.52
Price to Book (P/B)1.33
Price to Sales (P/S)3.03
P/FCF Ratio45.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.2
Revenue Forecast (FY)HK$1.39B
Jiangxi Rimag Group Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Jiangxi Rimag Group Co., Ltd. operates medical imaging centers in China. The company offers imaging examination and diagnostic service, such as MRI, CT, PET, X-ray, ultrasound, and mammography to patients and other healthcare consumers; imaging so...
Jiangxi Rimag Group Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
68
Positive
Cash Flow
52
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 873.12M | 760.59M | 928.91M | 784.44M | 592.01M |
| Gross Profit | 295.24M | 277.33M | 332.60M | 236.95M | 175.19M |
| EBITDA | 223.50M | 169.30M | 256.20M | 207.86M | -147.44M |
| Net Income | 3.75M | -45.92M | 44.41M | 364.00K | -360.73M |
Balance Sheet | |||||
| Total Assets | 2.86B | 2.26B | 1.88B | 1.99B | 2.06B |
| Cash, Cash Equivalents and Short-Term Investments | 626.16M | 262.79M | 215.79M | 355.62M | 509.67M |
| Total Debt | 622.72M | 578.61M | 386.02M | 489.07M | 574.76M |
| Total Liabilities | 853.70M | 779.76M | 543.54M | 673.18M | 752.48M |
| Stockholders Equity | 1.99B | 1.46B | 1.29B | 1.27B | 1.27B |
Cash Flow | |||||
| Free Cash Flow | 57.74M | -298.75M | 104.92M | -73.46M | -124.68M |
| Operating Cash Flow | 177.44M | 12.74M | 201.44M | 198.17M | 18.00M |
| Investing Cash Flow | -334.20M | -327.05M | -117.07M | -251.54M | -151.03M |
| Financing Cash Flow | 524.60M | 383.74M | -235.72M | -96.45M | 452.92M |
Jiangxi Rimag Group Co., Ltd. Class H Technical Analysis
Neutral
8.10
Price Trends
6.52
Negative
9.13
Negative
12.51
Negative
Market Momentum
-0.21
Negative
49.49
Neutral
72.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2522, the sentiment is Neutral. The current price of 8.1 is above the 20-day moving average (MA) of 5.10, above the 50-day MA of 6.52, and below the 200-day MA of 12.51, indicating a neutral trend. The MACD of -0.21 indicates Negative momentum. The RSI at 49.49 is Neutral, neither overbought nor oversold. The STOCH value of 72.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2522.
Jiangxi Rimag Group Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | HK$6.40B | 3.91 | 74.52% | ― | ― | ― | |
58 Neutral | HK$35.71B | 44.96 | 5.85% | ― | 33.20% | 34.66% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | HK$2.26B | 705.17 | 0.21% | ― | ― | ― | |
51 Neutral | HK$51.40B | -20.04 | -44.18% | ― | ― | ― | |
48 Neutral | HK$15.87B | -106.74 | -11.44% | ― | ― | ― | |
40 Neutral | HK$1.69B | -5.26 | -13.19% | ― | ― | ― |
* General Sector Average
HK:2522
Jiangxi Rimag Group Co., Ltd. Class H
5.64
-16.76
-74.82%
HK:9663
Sino-Synergy Hydrogen Energy Technology (Jiaxing) Co., Ltd. Class H
4.30
-4.40
-50.57%
HK:0666
Rept Battero Energy Company Ltd Class H
15.28
5.92
63.25%
HK:9880
UBTECH ROBOTICS CORP LTD Class H
102.10
39.35
62.71%
HK:2498
RoboSense Technology Company., Ltd
33.22
5.32
19.07%
HK:2598
Lianlian DigiTech Co., Ltd. Class H
5.69
-0.45
-7.33%
Jiangxi Rimag Group Co., Ltd. Class H Corporate Events
Jiangxi Rimag Group Publishes Audited 2025 Results and Previews Full Annual Report
Mar 31, 2026
Jiangxi Rimag Group Co., Ltd., a Hong Kong-listed joint stock company from mainland China, has a board structure that includes executive, non-executive and independent non-executive directors. The company provides bilingual disclosures and compreh...
Jiangxi Rimag Calls 2025 AGM to Approve Results, Capital Mandates and Board Changes
Mar 31, 2026
Jiangxi Rimag Group Co., Ltd., a Hong Kong–listed PRC joint stock company with a mixed board of executive, non-executive and independent non-executive directors, has announced arrangements for its 2025 annual general meeting to be held onlin...
Jiangxi Rimag Group Names Imaging Expert Meng Tao as Non-Executive Director
Mar 31, 2026
Jiangxi Rimag Group has nominated medical imaging specialist Meng Tao as a non-executive director for its second board term, with his appointment to take effect upon approval at an upcoming general meeting. Meng, a former physician at Fudan Univer...
Jiangxi Rimag Sets March 31 Board Meeting to Approve 2025 Results and Consider Dividend
Mar 19, 2026
Jiangxi Rimag Group Co., Ltd. has scheduled a board meeting for March 31, 2026 to review and approve the consolidated annual results for the year ended December 31, 2025. The board will also consider the publication of these results and decide whe...
Jiangxi Rimag Announces Routine Board Change as Non-Executive Director Resigns
Mar 3, 2026
Jiangxi Rimag Group Co., Ltd. announced that non-executive director and audit committee member Mr. Liu Senlin has tendered his resignation due to other work arrangements, effective upon the appointment of a new director. The board noted that Mr. L...
Jiangxi Rimag Extends RMB44 Million Credit Facility to Connected Subsidiaries
Feb 12, 2026
Jiangxi Rimag Group Co., Ltd. has entered into a loan facility agreement to provide up to RMB44 million in credit to its connected subsidiaries Rimag Yuntai and Wuhan Ronggongshe, setting a combined withdrawal cap for both borrowers. The transacti...
Jiangxi Rimag Grants 6.13 Million H Shares to Staff Under Performance-Based Award Scheme
Jan 23, 2026
Jiangxi Rimag Group Co., Ltd. has approved a grant of 6,130,000 existing H shares, equal to 1.55% of its issued share capital (excluding treasury shares), to 51 employees under its previously adopted share award scheme, including four directors an...
Jiangxi Rimag Shareholders Approve Dissolution of Supervisory Board and Governance Amendments
Jan 13, 2026
Jiangxi Rimag Group Co., Ltd. announced that shareholders approved a special resolution at an extraordinary general meeting held online on 13 January 2026, with about 40.46% of the company’s issued share capital (excluding treasury shares) r...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.